| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. | Principal Accounting Officer | Common Stock | 11.6K | $89.8K | $7.76 | May 7, 2024 | Direct |
| Fulcrum Therapeutics, Inc. | Principal Accounting Officer | Stock Option (right to buy) | 10K | Jan 26, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| FULC | Fulcrum Therapeutics, Inc. | May 7, 2024 | 1 | -$1.83K | 4 | May 9, 2024 | Principal Accounting Officer |
| FULC | Fulcrum Therapeutics, Inc. | Mar 8, 2024 | 1 | -$57.2K | 4 | Mar 8, 2024 | Vice President, Finance |
| FULC | Fulcrum Therapeutics, Inc. | Jan 26, 2024 | 2 | $0 | 4 | Jan 30, 2024 | Vice President, Finance |
| FULC | Fulcrum Therapeutics, Inc. | May 10, 2023 | 1 | -$695 | 4 | May 11, 2023 | Principal Accounting Officer |
| FULC | Fulcrum Therapeutics, Inc. | Feb 9, 2023 | 1 | $0 | 4 | Feb 13, 2023 | Controller |
| FULC | Fulcrum Therapeutics, Inc. | Jul 15, 2022 | 1 | $0 | 4 | Jul 19, 2022 | Controller |
| FULC | Fulcrum Therapeutics, Inc. | May 6, 2022 | 2 | $0 | 4 | May 10, 2022 | Controller |
| FULC | Fulcrum Therapeutics, Inc. | Mar 11, 2022 | 0 | $0 | 3 | Mar 14, 2022 | Controller |